NNC0638-0355 / Novo Nordisk - LARVOL DELTA

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=88 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Trial completion date: Nov 2025 ➔ Sep 2026 | Trial primary completion date: Sep 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=88 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=88 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Obesity